Recent advances in the treatment of colorectal liver metastases

Hepato-Gastroenterology

Volumn 52, Issue 65, 2005, Pages 1567-1584

  Jain, Sundeep ^a   Sacchi, M ^c   Vrachnos, P ^b   Lygidakis, N J ^a,d   Andriopoulou, E ^a  

^a HENRY DUNANT HOSPITAL   (Greece)

^b KAT HOSPITAL   (Greece)

^c SANTA MARIA GORETTI HOSPITAL   (Italy)

^d NONE   (Greece)

Author keywords

Colorectal liver metastases

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; AMIFOSTINE; CETUXIMAB; CISPLATIN; DEXAMETHASONE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; GEFITINIB; GELFOAM; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 6; IODINATED POPPYSEED OIL; IODINE 125; IODINE 131; IRIDIUM 192; IRINOTECAN; MELPHALAN; MITOMYCIN C; MITOXANTRONE; OXALIPLATIN; PIRARUBICIN; UNINDEXED DRUG; YTTRIUM 90;

ARTIFICIAL EMBOLISM; BIOLOGICAL THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHRONOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; HAIR LOSS; HEPATIC ARTERY; HUMAN; LIVER FAILURE; LIVER METASTASIS; LIVER TOXICITY; LOW LEVEL LASER THERAPY; MICROWAVE RADIATION; PORTAL VEIN; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; SCLEROSING CHOLANGITIS; VEIN OCCLUSION;

ANTINEOPLASTIC AGENTS; CATHETER ABLATION; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CHRONOTHERAPY; COLORECTAL NEOPLASMS; CRYOSURGERY; EMBOLIZATION, THERAPEUTIC; ETHANOL; GENE THERAPY; HEPATECTOMY; HEPATIC ARTERY; HUMANS; IMMUNOTHERAPY; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; LUNG NEOPLASMS; MICROWAVES; PATIENT SELECTION; PORTAL VEIN; PROGNOSIS; RADIOTHERAPY; RADIOTHERAPY DOSAGE;

EID: 25844498876     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (247)

1. Bengtsson G, Carlsson G, Hafström L, Jonsson PE: Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 1981; 141:586-589.
2. Finlay IG, McArdle CS: Occult hepatic metastases in colorectal carcinoma. Br J Surg 1986; 73:732-735.
3. Baden H, Andersen B: Survival of patients with untreated liver metastases from colorectal cancer. Scand J Gastroenterol 1975; 10:221-223.
4. Wagner JS, Adson MA, Van Heerden JA, Adson MH, Ilstrup DM: The natural history of hepatic metastases from colorectal cancer. Ann Surg 1984; 199:502-508.
5. Stangl R, Altendorf-Hofman A, Charnley R, Scheele J: Factors influencing the natural history of colorectal liver metastases. Lancet 1994; 343:1405-1410.
6. Scheele J, Stang R, Altendorf-Hofmann A: Hepatic metastases from colorectal carcinoma: Impact of surgical resection on the natural history. Br J Surg 1990; 77:1241-1246.
7. Wilson S, Adson M: Surgical treatment of hepatic metastases from colorectal cancers. Arch Surg 1976; 111:330-334.
8. Logan SE, Meier SJ, Ramming KP, Morton DL, Longmire WP Jr.: Hepatic resection for metastatic colorectal carcinoma: a ten year experience. Arch Surg 1982; 117:250-258.
9. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 1999; 230:309-318.
10. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, Jaeck D: Surgical resection of colorectal carcinoma metastases to the liver. Cancer 1996; 77:1254-1262.
11. Taylor M, Forster J, Langer B, Taylor BR, Greig PD, Mahut C: A study of prognostic factors for hepatic resection for colorectal metastases. Am J Surg 1997; 173:467.
12. Jamison RL, Donohue JH, Nagorney DM, Rosen CB, Harmsen WS, Ilstrup DM: Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg 1997; 132:505-511.
13. Cavallari A, Vivarelli M, Bellusci R, Montalti R, De Ruvo N, Cucchetti A, De Vivo A, De Raffele E, Salone M, La Barba G: Liver metastases from colorectal cancer: present surgical approach. Hepatogastroenterology 2003; 50(54):2067-2071.
14. Ciferri E, Bondanza GS, Municino O, Castagnola M, Gazzaniga GM: Colorectal cancer metastases: surgical indications and multimodal approach. Hepatogastroenterology 2003; 50(54):1836-1846.
15. Rees M, John TG: Current status of surgery in colorectal metastases to the liver. Hepatogastroenterology 2001; 48(38):341-344.
16. Fujii K, Fujioka S, Kato K, Machiki Y, Kutsuna Y, Ishikawa A, Takamizawa J, Mizutani T, Ko K, Yoshida K: Factors influencing survival in 33 patients undergoing resection of hepatic metastases from colorectal cancer. Hepatogastroenterology 2000; 47(33):607-611.
17. Poston G: The argument for liver resection in colorectal liver metastases. Hepatogastroenterology 2001; 48(38):345-346.
18. D'Angelica MI, Shoup MC, Nissan A: Randomized clinical trials in advanced and metastatic colorectal carcinoma. Surg Oncol Clin North Am 2002; 11:173-191.
19. Zieren HU, Muller JM, Zieren J: Resection of colorectal liver metastases in old patients. Hepatogastroenterology 1994; 41(1):34-37.
20. Blumgart LH, Fong Y: Surgical options in the treatment of hepatic metastasis from colorectal cancer. Curr Probl Surg 1995; 32:333-421.
21. Nordlinger B, Jaeck D, Guiguet M, et al: Surgical resection of hepatic metastases. Multicentric retrospective study by the French Association of Surgery. In: Nordlinger B, Jaeck D (Eds.). Treatment of hepatic metastases of colorectal cancer. Paris: Springer-Verlag; 1992; pp. 129-146.
22. Nuzzo G, Giuliante F, Giovannini I, Tebala GD, Clemente G, Vellone M: Resection of hepatic metastases from colorectal cancer. Hepatogastroenterology 1997; 44(15):751-759.
23. Steele G Jr, Ravikumar TS: Resection of hepatic metastases from colorectal cancer. Biologic perspective. Ann Surg 1989; 210:127-138.
24. Ekberg H, Tranberg KG, Andersson R, Lundstedt C, Hagerstrand I, Ranstam J, Bengmark S: Determinants of survival in liver resection for colorectal secondaries. Br J Surg 1986; 73:727-731.
25. Scheele J, Stangl R, Altendorf-Hofmann A, Paul M: Resection of colorectal liver metastases. World J Surg 1995; 19:59-71.
26. Bolton JS, Fuhrman GM: Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma. Ann Surg 2000; 231:743-751.
27. Minagawa M, Makuuchi M, Torzilli G, Takayama T, Kawasaki S, Kosuge T, Yamamoto J, Imamura H: Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long term results. Ann Surg 2000; 231:487-99.
28. Weber SM, Jarnagin WR, DeMatteo RP, Blumgart Lh, Fong Y: Survival after resection of multiple hepatic colorectal metastases. Ann Surg Oncol 2000; 7:643-650.
29. Tanaka K, Shimada H, Togo S, Ota M, Yamagichi S, Ike H: Is hepatic resection for multiple liver metastases from colorectal carcinoma acceptable treatment? Hepatogastroenterology 2001; 48:803-807.
30. Scheele J, Stangl R, Altendorf-Hofmann A: Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 1991; 110:13-29.
31. Pedersen IK, Burcharth F, Roikjaer O, Baden H: Resection of liver metastases from colorectal cancer. Indications and results. Dis Colon Rectum 1994; 37:1078-1082.
32. Hughes KS, et al: Resection of the liver for colorectal carcinoma metastases: A multi-institutional study of indications for resection. Registry of hepatic metastases. Surgery 1988; 103:278-288.
33. Elias D, Cavalcanti A, Sabourin JC, Lassau N, Pignon JP, Ducreux M, Coyle C, Lasser P: Resection of liver metastases from colorectal cancer: the real impact of the surgical margin. Eur J Surg Oncol 1998; 24:174-179.
34. Kokudo N, Miki Y, Sugai S, Yanagisawa A, Kato Y, Sakamoto Y, Yamamoto J, Yamaguchi T, Muto T, Makuuchi M: Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. Arch Surg 2002; 137:833-840.
35. Ohlsson B, Stenram U, Tranberg KG: Resection of colorectal liver metastases: 25-year experience. World J Surg 1998; 22:268-276.
36. Iwatsuki S, Dvorchik I, Madariaga JR, Marsh JW, Dodson F, Bonham AC, Geller DA, Gayowski TJ, Fung JJ, Starzl TE: Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 1999; 189:291-299.
37. Foster JH: Surgical treatment of metastatic liver tumors. Hepatogastroenterology 1990; 37(2): 182-187.
38. Adson M, Van Heerden J, Adson M, Wagner JS, Ilstrup DM: Resection of hepatic metastases from colorectal cancer. Arch Surg 1984; 119:647-651.
39. Yoshidome H, Ito H, Kimura F, Ambiru S, Shimizu H, Togawa A, Ohtsuka M, Kato A, Nukui Y, Miyazaki M: Surgical treatment for extrahepatic recurrence after hepatectomy for colorectal metastases. Hepatogastroenterology 2004; 51(60):1805-1809.
40. Headrick JR, Miller DL, Nagorney DM, Allen MS, Deschamps C, Trastek VF, Pairolero PC: Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg 2001; 71:975-979.
41. Seifert JK, Bottger TC, Weigel TF, Gonner U, Junginger T: Prognostic factors following liver resection for hepatic metastases from colorectal cancer. Hepatogastroenterology 2000; 47:239-246.
42. Yamada H, Katoh H, Kondo S, Okushiba S, Morikawa T: Mesenteric lymph nodes status influencing survival and recurrence pattern after hepatectomy for colorectal liver metastases. Hepatogastroenterology 2002; 49(47):1265-1268.
43. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, Marrero AM, Prasad M, Blumgart LH, Brennen MF: Liver resection for colorectal metastases. J Clin Oncol 1997; 15:938-946.
44. Seymour K, Charnley RM: Evidence that metastasis is less common in cirrhotic than normal liver: a systematic review of postmortem case-control studies. Br J Surg 1999; 86:1237-1243.
45. Karube H, Masuda H, Hayashi S, Ishii Y, Nemoto N: Fatty liver suppressed the angiogenesis in liver metastatic lesions. Hepatogastroenterology 2000; 47(36):1541-1545.
46. Tamura R, Masuda H, Ishii Y, Nemoto N: Relationship between fatty liver and liver metastasis in rats given injection of rat colon cancer cell line. Hepatogastroenterology 1999; 46(25):167-171.
47. Hayashi S, Masuda H, Shigematsu M: Liver metastasis is rare in colorectal cancer patients with fatty liver. Hepatogastroenterology 1997; 44:1069-1075.
48. Gervaz P, Pak-art R, Nivatvongs S, Wolff BG, Larson D, Ringel S: Colorectal adenocarcinoma in cirrhotic patients. J Am Coll Surg 2003; 196:874-879.
49. Laurent C, Cunha AS, Rullier E, Smith D, Rullier A, Saric J: Impact of microscopic hepatic lymph node involvement on survival after resection of colorectal liver metastasis. J Am Coll Surg 2004; 198:884-891.
50. Rodgers MS, McCall JL: Surgery for colorectal liver metastasis with hepatic lymph node involvement: a systematic review. Br J Surg 2000; 87:1142-1155.
51. Beckurts KT, Holscher AH, Thorban S, Bollschweiler E, Siewert JR: Significance of lymph node involvement at the hepatic hilum in the resection of colorectal liver metastasis. Br J Surg 1997; 84:1081-1084.
52. Harms J, Obst T, Thorban S, Busch R, Fink U, Heidecke CD, Roder JD, Siewert JR: The role of surgery in the treatment of liver metastases for colorectal cancer patients. Hepatogastroenterology 1999; 46(28):2321-2328.
53. Jaeck D, Nakano H, Bachellier P, Inoue K, Weber JC, Oussoultzoglou E, Wolf P, Chenard-Neu MP: Significance of hepatic lymph node involvement in patients with colorectal liver metastasis:a prospective study. Ann Surg Oncol 2002; 9:430-438.
54. Nordlinger B, Vaillant J, et al: A scoring system to select candidates for resection of colorectal liver metastases based on 1568 cases. SSO Abstract Book 1996; 17:11.
55. Doci R, Gennari L, Bignami P, Montalto F, Morabito A, Bozzetti F: One hundred patients with hepatic metastases from colorectal cancer treated by resection: analysis of prognostic determinants. Br J Surg 1991; 78:797-801.
56. Rees M, Plant G, Bygrave S: Late results justify resection for multiple hepatic metastases from colorectal cancer. Br J Surg 1997; 84:1136-1140.
57. Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, et al: Five year survival following hepatic resection after neoadjuvant therapy for non-resectable colorectal liver metastases. Ann Surg Oncol 2001; 8:347-353.
58. Azoulay D, Castaing D, Smail A, Adam R, Cailliez V, Laurent A, et al: Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann Surg 2000; 231:480-486.
59. Couinaud C: Le foie: etudes anatomiques et chirurgicales. Paris: Masson et Cie; 1957.
60. Azoulay D, Raccuia JS, Castaing D, Bismuth H: Right portal vein embolization in preparation for major hepatic resection. J Am Coll Surg 1995; 181:267-269.
61. Kawasaki S, Makuuchi M, Kakazu T, Miyagawa S, Takayama T, Kosuge T, et al: Resection for multiple metastatic liver tumors after portal embolization. Surgery 1994; 115:674-677.
62. Elias D, De Baere T, Roche A, Mducreux, Leclere J, Lasser P: During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br J Surg 1999; 86:784-788.
63. Kokudo N, Tada K, Seki M, Ohta H, Azekura K, Ueno M, et al: Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization. Hepatology 2001; 34:267-272.
64. Elias D, Ouellet JF, De Baere T, Lasser P, Roche A: Preoperative selective portal vein embolization before hepatectomy for liver metastases: Long-term results and impact on survival. Surgery 2002; 131:294-299.
65. Elias D, Goharin A, El Otmany A, Taieb J, Duvillard P, Lasser P, de Baere T: Usefulness of intraoperative radiofrequency thermoablation of liver tumors associated or not with hepatectomy. Eur J Surg Oncol 2000; 26:763-769.
66. Elias D, Debaere T, Muttillo I, Cavalcanti A, Coyle C, Roche A: Intraoperative use of radiofrequency treatment allows an increase in the rate of curative liver resection. J Surg Oncol 1998; 67:190-191.
67. Ercolani G, Principe A, Ravaioli M, Cescon M, Grazi GL: Long-term survival after two-stage hepatectomy for colorectal metastases: a case report. Hepatogastroenterology 2004; 51(56):592-594.
68. Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H: Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors. Ann Surg 2000; 232:777-785.
69. Kianmanesh R, Farges O, Abdalla EK, Sauvanet A, Ruszniewski P, Belghiti J: Right Portal Vein Ligation: A new planned two-step all-surgical approach for complete resection of primary gastrointestinal tumors with multiple bilateral liver metastases. J Am Coll Surg 2003; 197:164-170.
70. Lygidakis NJ, Singh G, Bardaxoglou E, Dedemadi G, Sgourakis G, Nestoridis J, Malliotakis A, Pedonomou M, Solomou EK, Safioleas M, Alamani M, Grigorakos L, Merikas EM: Two-stage liver surgery for advanced liver metastasis synchronous with colorectal tumor. Hepatogastroenterology 2004; 51:413-418.
71. Lodge JPA, Ammori BJ, Rajendra Prasad K, et al: Ex vivo and in situ resection of inferior vena cava with hepatectomy for colorectal metastases. Ann Surg 2000; 231:471-479.
72. Nakamura S, Suzuki S, Konno H, Baba S: Resection of metastatic liver tumors with special reference to hepatic venous system. Hepatogastroenterology 1998; 45:24-28.
73. Ohwada S, Takeyoshi I, Ogawa T, Ohya T, Saitoh A, Kawashima K, Iino Y, Morishita Y: Hepatic vein reconstruction at inferior vena cava confluence using left renal vein graft. Hepatogastroenterology 1998; 45:1833-1836.
74. Yamamoto Y, Terajima H, Ishikawa Y, et al: In situ pedicle resection in left trisegmentectomy of the liver combined with reconstruction of the right hepatic vein to an inferior vena caval segment transpositioned from the intrahepatic portion. J Am Coll Surg 2001; 192:137-141.
75. Aoki T, Sugawara Y, Imamura H, Seyama Y, Minagawa M, Hasegawa K, Kokudo N, Makuuchi M: Hepatic resection with reconstruction of the inferior vena cava or hepatic venous confluence for metastatic liver tumor from colorectal cancer. J Am Coll Surg 2004; 198:366-372.
76. Pichlmayr R: Is there a place for liver grafting for malignancy? Transpl Proc 1988; 20:478-82.
77. Schlag P, Hohenberger P, Herfarth C: Resection of liver metastases in colorectal cancer-competitive analysis of treatment results in synchronous versus metachronous metastases. Eur J Surg Oncol 1990; 16:360-365.
78. Jaeck D, Bachellier P, Weber JC: Surgical treatment of synchronous hepatic metastases of colorectal cancers. Simultaneous or delayed resection? Ann Chir 1996; 50:507-512.
79. Jenkins LT, Millikan KW, Bines SD, et al: Hepatic resection for metastatic colorectal cancer. Am Surg 1997; 63:605-610.
80. Fujita S, Akasu T, Moriya Y: Resection of synchronous liver metastases from colorectal cancer. Jpn J Clin Oncol 2000; 30:7-11.
81. Bismuth H, Castaing D, Traynor O: Surgery for synchronous hepatic metastases of colorectal cancer. Scand J Gastroenterol Suppl 1988; 149:144-149.
82. Elias D, Detroz B, Lasser P, et al: Is simultaneous hepatectomy and intestinal anastomosis safe? Am J Surg 1995; 169:254-260.
83. Jatzko G, Wette V, Muller M, et al: Simultaneous resection of colorectal carcinoma and synchronous liver metastases in a district hospital. Int J Colorectal Dis 1991; 6:111-114.
84. Vogt P, Raab R, Ringe B, Pichlmayr R: Resection of synchronous liver metastases from colorectal cancer. World J Surg 1991;15:62-67.
85. Martin R, Paty P, Fong Y, Grace A, Cohen A, DeMatteo R, Jarnagin W, Blumgart L: Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J Am Coll Surg 2003; 197:233-242.
86. Okumura S, Kondo H, Tsuboi M, et al: Pulmonary resection for metastatic colorectal cancer. J Thorac Cardiovasc Surg 1996; 112:867-874.
87. Girard P, Baldeyrou P, Le Chevalier T, et al: Surgery for pulmonary metastases. Who are the 10-year survivors? Cancer 1994; 74:2791-2797.
88. Inoue M, Kotake Y, Nakagawa K, et al: Surgery for pulmonary metastases from colorectal carcinoma. Ann Thorac Surg 2000; 70:380-383.
89. Irshad K, Ahmad F, Morin JE, Mulder DS: Pulmonary metastases from colorectal cancer: 25 years of experience. Can J Surg 2001; 44:217-221.
90. Mineo TC, Ambrogi V, Paci M, et al: Transxiphoid bilateral palpation in video-assisted thoracoscopic lung metastasectomy. Arch Surg 2001; 136:783-788.
91. Nagakura S, Shirai Y, Yamato Y, et al: Simultaneous detection of colorectal carcinoma liver and lung metastases does not warrant resection. J Am Coll Surg 2001; 193:153-160.
92. Regnard JF, Grunenwald D, Spaggiari L, et al: Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg 1998; 66:218-219.
93. Yamada H, Katoh H, Kondo S, et al: Surgical treatment of pulmonary recurrence after hepatectomy for colorectal liver metastases. Hepatogastroenterology 2002; 49:976-979.
94. Murata S, Moriya Y, Akasu T, et al: Resection of both hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer 1998; 83:1086-1093.
95. Mineo TC, Ambrogi V, Tonini G, Bollero P, Roselli M, Mineo D, Nofroni I: Long term results after resection of simultaneous and sequential lung and liver metastases from colorectal carcinoma. J Am Coll Surg 2003; 197:386-391.
96. Codi R, Gennari L, Bignami P, et al: One hundred patients with hepatic metastases from colorectal cancer treated by resection: Analysis of prognostic determinants. Br J Surg 1991; 78:797.
97. Fong Y, Blumgart L, Cohen A, et al: Repeat hepatic resections for metastatic colorectal cancer. Ann Surg 1994; 220:657.
98. Vagvolgyi A, Takacs I, Arkossy P, Peter M, Sapy P: Near total hepatectomy in two steps for surgical treatment of liver metastasis of colorectal tumor. Hepatogastroenterology 2003; 50(54):2176-2178.
99. Fukunaga K, Takada Y, Otsuka M, Todoroki T, Fukao K: Resection of localized recurrences after hepatectomy of colorectal cancer metastases. Hepatogastroenterology 2003; 50(54):1894-1897.
100. Taschieri AM, Elli M, Vignati GA, Montecamozzo G, Danelli PG, Kurihara H, Poliziani D: Repeated liver resection for recurrent metastases from colorectal cancer. Hepatogastroenterology 2003; 50(50):472-474.
101. Yamada H, Katoh H, Kondo S, Okushiba S, Morikawa T: Repeat hepatectomy for recurrent hepatic metastases from colorectal cancer. Hepatogastroenterology 2001; 48(39):828-830.
102. Chiappa A, Zbar AP, Biella F, Staudacher C: Survival after repeat hepatic resection for recurrent colorectal metastases. Hepatogastroenterology 1999; 46(26):1065-1070.
103. Gazzaniga GM, Ciferri E, Fazio S, Bagarolo C, Municino O, Cesaro S, Cogolo LA: Repeated hepatic resections for recurrent metastasis of colorectal cancer. Hepatogastroenterology 1995; 42(4):383-386.
104. Fernandez-Trigo V, Shamsa F, Aldrete J, et al: Repeat liver resections from colorectal metastasis. Repeat Hepatic Resection Registry. Cancer Treat Res 1994; 69:185-196.
105. Petrowsky H, Gonen M, Jarnagin W, et al: Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: A bi-institutional analysis. Ann Surg 2002; 235:863-871.
106. Kavolius J, Fong Y, Blumgart LH: Surgical resection of metastatic liver tumors. Surg Oncol Clin North Am 1996; 5:337-352.
107. Weiss L, Grandmann E, Torhost J, et al: Hematogenous metastatic patterns in colonic carcinoma: An analysis of 1541 necropsies. J Pathol 1986; 150:195-203.
108. Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D, et al: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224:509-522.
109. Sebagh M, Adam R, Lemoine A, Waechter F, Reynes M, Lévi F, et al: Evaluation histologique et biochimique de la toxicité hépatique d'une chimiothérapie systémique. Gastroenterol Clin Biol 1996; 20:A1.
110. Bognel C, Degott C, Rougier P, Lasser P, Elias D, Grandjouan S, et al: Etude anatomopathologique de la toxicité hépatique de la chimiothérapie intra-arterielle hé patique. Gastroenterol Clin Biol 1989; 13:125-131.
111. Elias D, Lasser P, Rougier P, Ducreux M, Bognel C, Roche A: Frequency, technical aspects, results and indications of major hepatectomy after prolonged intra-arterial hepatic chemotherapy for initially unresectable hepatic tumors. J Am Coll Surg 1995; 180:213-219.
112. Kemeny M, Goldberg D, Beatty J, et al: Results of a prospective randomized trial of continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal cancer. Cancer 1986; 57:492-498.
113. Kemeny N, Huang Y, Cohen AM, et al: Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341:2039-2048.
114. Kemeny MM, Adak S, Gray B, et al: Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy - an intergroup study. J Clin Oncol 2002; 20:1499-1505.
115. Lorenz M, Muller H-H, Schramm H, et al: Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. Surg 1998; 228:756-762.
116. Nonami T, Takeuchi Y, Yasui M, et al: Regional adjuvant chemotherapy after partial hepatectomy for metastatic colorectal carcinoma. Semin Oncol 1997; 24:56-130.
117. Asahara T, Kikkawa M, Okajima M, Ojima Y, Toyota K, Nakahara H, Katayama K, Itamoto T, Marubayashi S, One E, Yahata H, Dohi K, Azuma K, Ito K: Studies of postoperative transarterial infusion chemotherapy for liver metastasis of colorectal carcinoma after hepatectomy. Hepatogastroenterology 1998; 45:805-811.
118. Okuno K, Shigeoka H, Lee YS, Son E, Kayama H, Nakai T, Koh K, Yasutomi M: Adjuvant hepatic arterial IL-2 and MMC, 5-FU after curative resection of colorectal liver metastases. Hepatogastroenterology 1996; 43(9):688-691.
119. Portier G, Rougier P, Milan C, et al: Adjuvant systemic chemotherapy using 5-fluorouracil and folinic acid after resection of liver metastases from colorectal origin. Proc Am Soc Clin Oncol 2002; 21:133a.
120. Kemeny N, Lokich JJ, Anderson N, Ahlgren JD: Recent advances in the treatment of advanced colorectal cancer. Cancer 1993; 71:9-18.
121. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000; 355:1041-1047.
122. Goldberg R, Morton R, Sargent D, et al: Oxaliplatin (Oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 2002; 21:511.
123. Glimelius B, Hoffman K, Olafsdottir M, Pahlman L, Sjoden PO, Wennberg A: Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma: A randomized comparison of two regimens. Eur J Cancer Clin Oncol 1989; 25:829-835.
124. Allen-Mersh T, Earlam S, Fordy C, Abrams K, Houghton J: Quality of life and survival with continuous hepatic artery floxuridine infusion for colorectal liver metastases. Lancet 1994; 344:1255-1260.
125. Ragnhammar P, Hafstrom L, Nygren P, Glimelius B: A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 2001; 40:282-308.
126. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidi J, et al: Leucovorin and 5-FU with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947.
127. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343:905-914.
128. Breedis C, Young C: The blood supply of neoplasms in the liver. Am J Pathol 1954; 30:969.
129. Mathur P, Allen-Mersh TG: Hepatic arterial chemotherapy for colorectal liver metastases. Hepatogastroenterology 2001; 48:317-319.
130. Ensminger WD, Rosowsky A, Raso V: A clinical pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2-deoxyuridine and 5-fluorouracil. Cancer Res 1978; 38:3789-3792.
131. Ensminger WD, Gyves JW: Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol 1983; 10:176-183.
132. Van Groeningen C, Vandervijgh W, Giaccone G, et al: Phase I clinical and pharmacokinetic study of 5 day CPT-11 hepatic arterial infusion (HAI) chemotherapy. Proc ASCO 1997; 16:A768.
133. Collins JM: Pharmacologic rationale for regional drug delivery. J Clin Oncol 1984; 2:498-504.
134. Kemeny N, Daly J, Reichman B, et al: Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma - a randomized trial. Ann Intern Med 1987; 107:459-467.
135. Hohn D, Stagg R, Friedman M, et al: A randomized trial of continuous intravenous versus hepatic intra-arterial floxuridine in patients with colorectal cancer metastatic to the liver: The Northern California Oncology Group Trial. J Clin Oncol 1989; 7:1646-1654.
136. Chang AE, Schneider PD, Sugarbaker PH: A prospective randomized trial of regional versus systemic continuous 5-flouoroxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987; 206:685-693.
137. Martin JKJ, O'Connell MG, Wieland HS, et al: Intraarterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 1990; 125:1022.
138. Rougier P, Laplanche A, Huguier M, et al: Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: Long-term results of a prospective randomized trial. J Clin Oncol 1992; 10:1112-1118.
139. Lorenz M, Muller HH: Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000; 18:243-254.
140. McArdle C, Kerr D, Ledermann J, et al: Intravenous (IV) vs intrahepatic arterial (IHA) 5FU/leucovorin for colorectal (CRC) liver metastases: Preliminary results of the MRC CR05/EORTC 40972 randomised trial. Am Soc Clin Oncol 2001; 20:126a.
141. Meta-Analysis GiC: Reappraisal of HAI in the treatment of nonresectable liver metastases from colorectal carcinoma. J Natl Cancer Inst 1996; 88:252-258.
142. Kemeny N, Steiter K, Diedzweiecki D, et al: A randomized trial of intrahepatic infusion of fluorouridine (FUDR) with dexamethasone versus FUDR alone in the treatment of metastatic colorectal cancer. Cancer 1992; 69:327-334.
143. Stagg R, Venook A, Chase J, et al: Alternating hepatic intra-arterial floxuridine and fluorouracil: A less toxic regimen for treatment of liver metastases from colorectal cancer. J Natl Cancer Inst 1991; 83:423-428.
144. Davidson B, Izzo F, Chase J, et al: Alternating floxuridine and 5-fluorouracil hepatic arterial chemotherapy for colorectal liver metastases minimizes biliary toxicity. Am J Surg 1996; 172:244-247.
145. Warren H, Anderson J, O'Gorman P, et al: A Phase II study of regional 5-fluorouracil infusion with intravenous folinic acid for colorectal liver metastases. Br J Cancer 1994; 70:677-680.
146. Metzger U, Weder W, Rothlin M, Largiader F: Phase II study of intra-arterial fluorouracil and mitomycin-C for liver metastases of colorectal cancer. Recent Results Cancer Res 1991; 121:198-204.
147. Hrushesky W, Von Roemelling R, Lanning R, Rabtini J: Circadian shaped infusions of floxuridine for progressive metastatic renal cell carcinoma. J Clin Oncol 1990; 8:1504-1513.
148. Kemeny N, Cohen A, Steiner K, et al: Randomized trial of hepatic arterial FUDR, Mitomycin and BCNU versus FUDR alone: Effective salvage therapy for liver metastases of colorectal cancer. J Clin Oncol 1993; 11:330-335.
149. Kemeny N, Cohen A, Bertino J, et al: Continuous intrahepatic infusion of floxuridine and leucovorin through an implantable pump for the treatment of hepatic metastases from colorectal carcinoma. Cancer 1990; 65:2446-2450.
150. Kemeny N, Conti JA, Cohen A, et al: Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresected liver metastases from colorectal carcinoma. J Clin Oncol 1994; 12:2288-2295.
151. Link KH, Sunelaitis E, Kornmann M, Schatz M, Gansauge F, Leder G, et al: Regional chemotherapy of nonresectable colorectal liver metastases with mitoxantrone, 5-fluorouracil, folinic acid, and mitomycin C may prolong survival. Cancer 2001; 92(11):2746-2753.
152. Piedbois P: Intravenous CPT-11/5-FU/LV and hepatic artery infusion of pirarubicin in non operable liver metastases from colorectal cancer. A study of the A.E.R.O. Group. Ann Oncol 2002; 13(Suppl 5):80-81.
153. Paty P, Kemeny N, Tong W, Sullivan D, Fong Y, Jarnagin W: A phase I/II study of hepatic arterial infusion (HAI) of floxuridine (FUDR) and dexamethasone (DEX) with systemic irinotecan (CPT-11) for unresectable hepatic metastases from colorectal cancer. Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 2001; 19:260a.
154. Ducreux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Husseini F, et al: Intra-arterial hepatic chemotherapy (IAHC) with oxaliplatin (O) combined to intravenous treatment with 5-FU + folinic acid (FA) in hepatic metastases of colorectal cancer (HMCC). Final results of a trial of the french federation of anticancer centers. Proceedings of the Thirty-Ninth Annual Meeting of the American Society of Clinical Oncology, May 2003, Chicago, IL. 2003; 22:278, A1115.
155. Boige V, Lacombe S, de Baere T, Pocard M, Elias D, Lasser P, et al: Hepatic arterial infusion of oxaliplatin combined with intravenous 5-FU and folinic acid in non resectable liver metastasis of colorectal cancer: a promising option for failures to systemic chemotherapy. Proceedings of the Thirty-Ninth Annual Meeting of the American Society of Clinical Oncology, May 2003, Chicago, IL. 2003; 22:292, A1170.
156. Melichar B, Dvorak J, Jandik P, Touskova M, Malirova E, Megancova J, Voboril Z: Regional administration of irinotecan in combination with 5-fluorouracil and leucovorin in patients with colorectal cancer liver metastases-a pilot experience. Hepatogastroenterology 2001; 48(42):1721-1726.
157. Safi F, Bittner R, Roscher R, Schuhmacher K, Graus W, Beger G: Regional chemotherapy for hepatic metastases of colorectal carcinoma (continous intra-arterial versus continuous intra-arterial/intravenous therapy). Cancer 1989; 64:379-387.
158. Lorenz M, Hottenrott C, Inglis R, Kirkowa-Reimann M: Prevention of extrahepatic disease during intra-arterial floxuridine of colorectal liver metastases by simultaneous systemic 5-fluorouracil treatment? A prospective multicenter study. Gan To Kagaku Ryoho 1989; 12:3662.
159. Gorlick R, Metzger R, Danenberg KD, et al: Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma. J Clin Oncol 1998; 16:1465-1469.
160. Kornmann M, Link K, Lenz H, et al: Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. Cancer Letters 1997; 118:29-35.
161. Saltz L, Danenberg P, Paty P, et al: High thymidylate synthase (TS) expression does not preclude activity of CPT-11 in colorectal cancer (CRC). Proc Am Soc Clin Oncol 1998; 17:281a.
162. Popov I, Lavrnic S, Jelic S, Jezdic S, Jasovic A: Chemoembolization for liver metastases from colorectal carcinoma: Risk or a benefit. Neoplasma 2002; 49:43-48.
163. Bavisotto LM, Patel NH, Althaus SJ, et al: Hepatic transcatheter arterial chemoembolization alternating with systemic protracted continuous infusion 5-fluorouracil for gastrointestinal malignancies metastatic to liver: A phase II trial of the Puget Sound Oncology Consortium (PSOC 1104). Clin Cancer Res 1999; 5:95-109.
164. Muller H, Nakchbandi V, Chatzisavvidis I, von Voigt C: Repetitive chemoembolization with melphalan plus intra-arterial immuno-chemotherapy within 5-fluorouracil and granulocyte-macrophage colony-stimulating factor (GM-CSF) as effective first- and second-line treatment of disseminated colorectal liver metastases. Hepatogastroenterology 2003; 50(54):1919-1926.
165. Fiorentini G, Poddie DB, Cantore M, Giovanis P, Guadagni S, De Giorgi U, Cariello A, Dazzi C, Turci D: Locoregional therapy for liver metastases from
166. Marinelli A, de Brauw LM, Beerman H, et al: Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver. Jpn J Clin Oncol 1996; 26:341-350.
167. Van Zuidewign D, de Brauw L, Marinelli A, et al: Isolated liver perfusion with Mitomycin-C or melphalan in patients with hepatic metastases. Soc Surg Oncol 1993; 46:198.
168. Alexander H, Bartlett D, Libutti S, Fraker D, Moser T, Rosenberg S: Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 1998; 16:1479-1489.
169. de Vries MR, Borel Rinkes IHM, Swaak AJ, et al: Acute-phase response patterns in isolated hepatic perfusion with tumour necrosis factor alpha (TNF-alpha) and melphalan in patients with colorectal liver metastases. Eur J Clin Invest 1999; 29:553-560.
170. Levi F, Giacchetti S, Zidani R, Brezault-Bonnet C, Tigaud JM, Goldwasser F, Misset JL: Chronotherapy of colorectal cancer metastases. Hepatogastroenterology 2001; 48:320-322.
171. Levi F: Chronotherapy for gastrointestinal cancers. Curr Opin Oncol 1996; 8:334-341.
172. Levi F, Zidani R, Vannetzel JM, et al: Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with colorectal cancer metastases. A randomized multiinstitutional trial. J Natl Cancer Ins 1994; 86:1608-1617.
173. Levi F, Zidani R, Misset JL: Randomized multicenter trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997; 350:681-686.
174. Levi F, Zidani R, Brienza S, et al: A multicenter evaluation of intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal cancer. Cancer 1999; 85:2532-2540.
175. Bertheault-Cvitkovic F, Jami A, Ithzaki M, Brummer PD, Brienza S, Adam R, et al: Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 1996; 14:2950-2958.
176. Ogata K, Hizawa K, Yoshida M, et al: Hepatic injury following irradiation - a morphologic study. Tukushima J Exp Med 1963; 9:240.
177. Bruso CE, Shewach DS, Lawrence TS: Fluorodeoxyuridine-induced radiosensitization and inhibition of DNA double strand break repair in human colon cancer cells. Int J Radiat Oncol Biol Phys 1990; 19:1411-1417.
178. Gray B, Van Hazel G, Hope M, et al: Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001; 12:1711-1720.
179. Stubbs RS, Cannan RJ, Mitchell AW: Selective internal radiation therapy (SIRT) with 90-yttrium microspheres for extensive colorectal liver metastases. Hepatogastroenterology 2001; 48:333-337.
180. Thomas D, Nauta R, Rodgers J, et al: Intraoperative high dose rate interstitial irradiation of hepatic metastases from colorectal carcinoma. Results of a Phase I-II trial. Cancer 1993; 71:1977-1981.
181. Donath D, Nori D, Turnbull A, Kaufman N, Fortner J: Brachytherapy in the treatment of solitary colorectal metastases to the liver. J Surg Oncol 1990; 44:55-61.
182. Mohiuddin M, Chen E, Ahmad J: Combined liver radiation and chemotherapy for palliation of hepatic metastases from colorectal cancer. J Clin Oncol 1996; 14:722-728.
183. Dawson LA, McGinn CJ, Normolle D, et al: Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 2000; 18:2210-2218.
184. Balter J, Brock K, Litzenberd D, et al: Daily targeting of intrahepatic tumors for radiotherapy. Int J Radiat Oncol Biol Phys 2002; 52:266-271.
185. Gunven P, Blomgren H, Lax I: Radiosurgery for recurring liver metastases after hepatectomy. Hepatogastroenterology 2003; 50(53):1201-1204.
186. Fiorentini G, Giovanis P, Leoni M, De Giorgi U, Cariello A, Dazzi C, Caldeo A: Amifostine (ethyol) as modulator of hepatic and biliary toxicity from intraarterial hepatic chemoembolization: results of a phase I study. Hepatogastroenterology 2001; 48:313-316.
187. Symon Z, Levi M, Ensminger W, et al: Selective radioprotection of hepatocytes by systemic and portal vein infusions of amifostine in rat liver model. Int J Radiat Oncol Biol Phys 2001; 50:473-478.
188. Livraghi T, Bolondi L, Buscarini L, Cottone M, Mazziotti A, Morabito A, et al: No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Italian cooperative HCC study group. J Hepatol 1995; 22(5):522-526.
189. Bartolozzi C, Lencioni R: Ethanol injection for the treatment of hepatic tumours. Eur Radiol 1996; 6(5):682-696.
190. Giovannini M, Seitz JF: Ultrasound-guided percutaneous alcohol injection of small liver metastases. Results in 40 patients. Cancer 1994; 73(2):294-297.
191. Giorgio A, Tarantino L, Mariniello N, De Stefano G, Perrotta A, Aloisio V, et al: Ultrasonography-guided percutaneous ethanol injection in large an/or multiple liver metastasis. Radiol Med (Torino) 1998; 96(3):238-242.
192. Mazziotti A, Grazi GL, Gardini A, Cescon M, Pierangeli F, Ercolani G, et al: An appraisal of percutaneous treatment of liver metastases. Liver Transpl Surg 1998; 4(4):271-275.
193. Poston G: Cryosurgery for colorectal liver metastases. Hepatogastroenterology 2001; 48:323-324.
194. Neeleman N, Wobbes T, Jager GJ, Ruers TJM: Cryosurgery as treatment modality for colorectal liver metastases. Hepatogastroenterology 2001; 48:325-329.
195. Litvak DA, Wood TF, Tsioulias GJ, et al: Systemic irinotecan and regional floxuridine after hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases. Ann Surg Oncol 2002; 9:148-155.
196. Seifert JK, Morris DL: Prognostic factors after cryotherapy for hepatic metastases from colorectal cancer. Ann Surg 1998; 228(2):201-208.
197. Adam R, Akpinar E, Johann M, Kunstlinger F, Majno P, Bismuth H: Place of cryosurgery in the treatment of malignant liver tumors. Ann Surg 1997; 225(1):39-48.
198. Onik G, Rubinsky B, Zemel R, Weaver L, Diamond D, Cobb C, et al: Ultrasound-guided hepatic cryosurgery in the treatment of metastatic colon carcinoma. Preliminary results. Cancer 1991; 67(4):901-907.
199. Weaver ML, Atkinson D, Zemel R: Hepatic cryosurgery in treating colorectal metastases. Cancer 1995; 76:210-214.
200. Preketes AP, Caplehorn JR, King J, Clingan PR, Ross WB, Morris DL: Effect of hepatic artery chemotherapy on survival of patients with hepatic metastases from colorectal carcinoma treated with cryotherapy. World J Surg 1995; 19(5):768-771.
201. Morris D, Ross W: Australian experience of cryoablation of liver tumors: Metastases. Surg Oncol Clin NA 1996; 5:391-397.
202. Bilchik AJ, Wood TF, Allegra D, Tsioulias GJ, Chung M, Rose DM, et al: Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms: a proposed algorithm. Arch Surg 2000; 135(6):657-662.
203. Welling R, Lamping K: Cryoprobe as a "handle" for resection of metastatic liver tumors. J Surg Oncol 1990; 45:227-228.
204. McGahan JP, Browning PD, Brock JM, Tesluk H: Hepatic ablation using radiofrequency electrocautery. Invest Radiol 1990; 25(3):267-270.
205. Goldberg SN, Gazelle GS: Radiofrequency tissue ablation: Physical principles and techniques for increasing coagulation necrosis. Hepatogastroenterology 2001; 48:359-367.
206. Machi J, Uchida S, Sumida K, Limm WM, Hundahl SA, Oishi AJ, et al: Ultrasoundguided radiofrequency thermal ablation of liver tumors: percutaneous, laparoscopic, and open surgical approaches. J Gastrointest Surg 2001; 5(5):477-489.
207. Solbiati L, Ierace T, Goldberg SN, Sironi S, Livraghi T, Fiocca R, et al: Percutaneous US-guided radio-frequency tissue ablation of liver metastases: treatment and follow-up in 16 patients. Radiology 1997; 202(1):195-203.
208. Solbiati L, Livraghi T, Goldberg SN, Ierace T, Meloni F, Dellanoce M, et al: Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 2001; 221(1):159-166.
209. Wong SL, Edwards MJ, Chao C, Simpson D, McMasters KM: Radiofrequency ablation for unresectable hepatic tumors. Am J Surg 2001; 182(6):552-557.
210. Curley SA, Izzo F, Delrio P, Ellis LM, Granchi J, Vallone P, et al: Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg 1999; 230(1):1-8.
211. Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN: Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 2003; 226(2):441-451.
212. Pearson AS, Izzo F, Fleming RY, Ellis LM, Delrio P, Roh MS, et al: Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg 1999; 178(6):592-599.
213. Azzarello G, Lanteri R, Gresta S, Rapisarda C, Racalbuto A, Di Cataldo A, Licata A: Thermic ablation with RF of liver metastases from colorectal cancer. Hepatogastroenterology 2003; 50(Suppl 2):ccv-ccvii.
214. Elias D, Santoro R, Ouellet JF, Osmak L, de Baere T, Roche A: Simultaneous percutaneous right portal vein embolization and left liver tumor radiofrequency ablation prior to a major right hepatic resection for bilateral colorectal metastases. Hepatogastroenterology 2004; 51(60):1788-1791.
215. Julianov A, Karashmalakov A, Rachkov I, Hristov H: Treatment of colorectal cancer with synchronous bilobar liver metastases with simultaneous bowel and liver resection plus radiofrequency ablation. Hepatogastroenterology 2004; 51(57):643-645.
216. Kainuma O, Asano T, Aoyama H, Takayama W, Nakagohri T, Kenmochi T, Hasegawa M, Tokoro Y, Sasagawa S, Ochiai T: Combined therapy with radiofrequency thermal ablation and intra-arterial infusion chemotherapy for hepatic metastases from colorectal cancer. Hepatogastroenterology 1999; 46(26):1071-1077.
217. Shetty SK, Rosen MP, Raptopoulos V, Goldberg SN: Cost-effectiveness of percutaneous radiofrequency ablation for malignant hepatic neoplasms. J Vasc Interv Radiol 2001; 12(7):823-833.
218. Goldberg SN, Gazelle GS, Compton CC, Mueller PR, Tanabe KK: Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation. Cancer 2000; 88(11):2452-2463.
219. Langenho BS, Oyen WJ, Jager GJ, Strijk SP, Wobbes T, Corstens FH, et al: Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol 2002; 20(22):4453-4458.
220. Tabuse K: A new operative procedure of hepatic surgery using a microwave tissue coagulator. Nippon Geka Hokan 1979; 48(2):160-172.
221. Shibata T, Niinobu T, Ogata N, Takami M: Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma. Cancer 2000; 89(2):276-284.
222. Idani H, Narusue M, Kin H, Uda K, Muro M, Kaneko A, Sasaki H, Watanabe K, Takahashi K: Hepatic resection for liver metastasis of sigmoid colon cancer after incomplete percutaneous microwave coagulation therapy. Hepatogastroenterology 2001; 48:244-246.
223. Vogl TJ, Muller PK, Mack MG, Straub R, Engelmann K, Neuhaus P: Liver metastases: interventional therapeutic techniques and results, state of the art. Eur Radiol 1999; 9(4):675-684.
224. Gillams AR, Lees WR: Survival after percutaneous, image-guided, thermal ablation of hepatic metastases from colorectal cancer. Dis Colon Rectum 2000; 43(5):656-661.
225. Masters A, Steger AC, Lees WR, Walmsley KM, Bown SG: Interstitial laser hyperthermia: a new approach for treating liver metastases. Br J Cancer 1992; 66:518-522.
226. Usatoff V, Habib NA: Update of laser-induced thermotherapy for liver tumors. Hepatogastroenterology 2001; 48:330-332.
227. Bartolozzi C, Crocetti L, Cioni D, Donati FM, Lencioni R: Assessment of therapeutic effect of liver tumor ablation procedures. Hepatogastroenterology 2001; 48:352-358.
228. O'Dwyer PJ, Benson AB 3rd: Epidermal growth factor receptor-targeted therapy in colorectal cancer. Semin Oncol 2002; 29:10-17.
229. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, et al: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20:4292-4302.
230. Divgi CR, Scott AM, Gulec S, Broussard EK, Levy N, Young C, et al: Pilot radioimmunotherapy trial with 131I-labeled murine monoclonal antibody CC49 and deoxyspergualin in metastatic colon carcinoma. Clin Cancer Res 1995; 1:1503-1510.
231. Hirata A, Ogawa S, Kometani T, Kuwano T, Naito S, Kuwano M, et al: ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002; 62:2554-2560.
232. Grem JL, Jordan E, Robson ME, Binder RA, Hamilton JM, Steinberg SM, et al: Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma. J Clin Oncol 1993; 11:1737-1745.
233. Hausmaninger H, Moser R, Samonigg H, Mlineritsch B, Schmidt H, Pecherstorfer M, et al: Biochemical modulation of 5-fluorouracil by leucovorin with or without interferonalpha-2c in patients with advanced colorectal cancer: final results of a randomized phase III study. Eur J Cancer 1999; 35:380-385.
234. Fountzilas G, Zisiadis A, Dafni U, Konstantaras C, Hatzitheoharis G, Papavramidis S, et al: Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Oncology 2000; 58:227-236.
235. Patt YZ, Mavligit GM: Arterial chemotherapy in the management of colorectal cancer: an overview. Semin Oncol 1991; 18:478-490.
236. Okuno K, Hirohata T, Nakamura K, Jinnai H, Shigeoka H, Koh K, et al: Hepatic arterial infusions of interleukin-2-based immunochemotherapy in the treatment of unresectable liver metastases from colorectal cancer. Clin Ther 1993; 15:672-683.
237. Lygidakis NJ, Savanis G, Pothoulakis J, Kapetanakis A: Transarterial locoregional immunostimulation and chemotherapy in patients with unresectable secondary liver tumours. Anticancer Res 1994; 14:643-646.
238. Okuno K, Kaneda K, Yasutomi M: Regional IL-2-based mmunochemotherapy of colorectal liver metastases. Hepatogastroenterology 1999; 46(Suppl 1):1263-1267.
239. Lygidakis NJ, Ziras N, Parissis J: Resection versus resection combined with adjuvant pre- and post-operative chemotherapy-immunotherapy for metastatic colorectal liver cancer. A new look at an old problem. Hepatogastroenterology 1995; 42:155-161.
240. Lygidakis NJ, Stringaris K, Kokinis K, Lyberopoulos K, Raptis R: Locoregional chemotherapy versus locoregional combined immuno-chemotherapy for patients with advanced metastatic liver disease of colorectal origin: a prospective randomized study. Hepatogastroenterology 1996; 43:212-220.
241. Lygidakis NJ, Sgourakis G, Vlachos L, Raptis S, Safioleas M, Boura P, Kountouras J, Alamani M: Metastatic liver disease of colorectal origin: the value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection. Results of a prospective randomized study. Hepatogastroenterology 2001; 48:1685-1691.
242. Okuno K, Yasutomi M, Kon M, Hatakeyama K, Muto T, Kitajima M, Koyanagi Y, Hamano K, Ohta H, Aiba K, Arai Y, Sowa M, Kikkawa N, Takayasu Y, Isomoto H: Intrahepatic interleukin-2 with chemotherapy for unresectable liver metastases: a randomized multicenter trial. Hepatogastroenterology 1999; 46(26):1116-1121.
243. Wildner O, Blaese RM, Candotti F: Enzyme prodrug gene therapy: synergistic use of the herpes simplex virus-cellular thymidine kinase/ganciclovir system and thymidylate synthase inhibitors for the treatment of colon cancer. Cancer Res 1999; 59:5233-5238.
244. Sung MW, Yeh HC, Thung SN, Schwartz ME, Mandeli JP, Chen SH, et al: Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial. Mol Ther 2001; 4:182-191.
245. Mazzolini G, Qian C, Narvaiza I, Barajas M, Borras-Cuesta F, Xie X, et al: Adenoviral gene transfer of interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effector level. Hum Gene Ther 2000; 11:113-125.
246. Rubin J, Galanis E, Pitot HC, Richardson RL, Burch PA, Charboneau JW, et al: Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7. Gene Ther 1997; 4:419-25.
247. Habib NA, Sarraf CE, Mitry RR, Havlik R, Nicholls J, Kelly M, et al: E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum Gene Ther 2001; 12:219-26.